| abstract |
A pharmaceutical composition for treatment of Multiple Sclerosis is disclosed, comprising monolamellar liposomes having the size of 100 nm to 200 nm, wherein the liposomes comprise a mixture containing 1 part by weight of tetramannosyl-3-L-lysine-dioleoyl glycerol and 99 parts by weight of 2,3-dipalmitoyl-sn-glycero-1-phosphatydyl choline, and includes the following oligopeptides: GGDRGAPKRGSGKDSHH; GFGYGGRASDYKSAHK; QGTLSKIFKLGGRDSRSGSPMARR, which are myelin basic protein fragments. A method for treatment of Multiple Sclerosis, comprising administering said pharmaceutical composition to a patient in need thereof is also disclosed. |